Dehydration behavior and structural characterization of the GW275919X monohydrate.
GW275919X, a central muscle relaxant for the treatment of lower back pain, exists in a monohydrate. Knowledge of the solid state dehydration behavior and the crystal structure is essential for determining its relative physical stability. Thermal analysis and hot-stage powder X-ray diffraction were used to study the solid state phase transformation during the dehydration process. Crystal structure was determined by single crystal X-ray analysis. Molecular modeling with Cerius(2) software was used to visualize the hydrate crystal structure and to construct the molecular packing and hydrogen bond diagram. Morphology prediction was performed using the BFDH calculation. Crystallographic data: monoclinic, space group, P21/c, a (Angstrom)=14.3734, b (Angstrom)=5.0336, c (Angstrom)=15.4633 and beta=105.11 degrees. Water molecules in the hydrate crystal of GW275919X are involved in the hydrogen bonds and these hydrogen bonds contribute to the coherence of the crystal structure. The longest dimension of the predicted morphology is in the b-direction, which would correspond to the needle axis of the experimental crystals.
Strategic Technologies, GlaxoSmithKline Inc., Five Moore Drive, Research Triangle Park, NC 27709, USA. jim.zhu@frx.com
Haijian Jim
HJ
Zhu
D001562:Benzimidazoles / Q000737:chemistry* / Q000627:therapeutic use; D018360:Crystallography, X-Ray; D005464:Fluorobenzenes / Q000737:chemistry* / Q000627:therapeutic use; D006860:Hydrogen Bonding; D017116:Low Back Pain / Q000188:drug therapy*; D008958:Models, Molecular; D015394:Molecular Structure; D009125:Muscle Relaxants, Central / Q000737:chemistry*; D044367:Phase Transition; D012263:Ribonucleosides / Q000737:chemistry* / Q000627:therapeutic use; D013696:Temperature; D014867:Water
C486447:2-bromo-5,6-dichloro-1-ribopyranosyl-1H-benzimidazole; D001562:Benzimidazoles; D005464:Fluorobenzenes; C515587:GW275919X; D009125:Muscle Relaxants, Central; D012263:Ribonucleosides; D014867:Water